Programs to be Driven Through Patented AI Technology and Advanced Proprietary B Cell Platforms Partnership advances next-generation ADCs and bispecific antibodies to address unmet medical needs AUSTIN, Texas, March 13, 2025—ImmunoPrecise Antibodies Ltd. (IPA) (NASDAQ: […]
Unusual Machines (NYSE: UMAC) CEO Interview with Allan Evans Unusual Machines (NYSE: UMAC) CEO Allan Evans discusses UMAC growth strategy in multi-billion dollar US drone market. While the drone market is booming, Evans sees the […]
HOUSTON, March 06, 2025 — Plus Therapeutics, Inc. (NASDAQ: PSTV) (the “Company” or “Plus Therapeutics”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announces that the […]
FDA concludes site inspection is closed under 21 C.F.R.20.64(d)(3); Voluntary Action Indicated Company believes this further supports reliability of data from TRANQUILITY II trial of BXCL501 NEW HAVEN, Conn., March 03, 2025 — BioXcel Therapeutics, […]
– The Company today reported positive initial results from the ongoing FREEDOM-DM1 trial in patients with DM1; mean splicing correction of 12.3% and 29.1% in 5 and 10 mg/kg cohorts, respectively – – FREEDOM-DM1 15 […]
ScanTech AI is leading the charge in combating contraband in correctional facilities with cutting-edge artificial intelligence merged with advanced CT scanning technology Atlanta, GA, Feb. 18, 2025 — ScanTech AI Systems Inc. (NASDAQ: STAI) (“ScanTech […]
GARDEN CITY, NY, Feb. 18, 2025 — ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next-generation biotech, genomics, and consumer products company, today announced the appointment of Stu Hollenshead as Chief Operating Officer, […]
NASHVILLE, Tenn., Feb. 4, 2025 — Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company with development efforts focused on new products for rare diseases, today announced positive top-line results from its Phase 2 FIGHT DMD trial. […]
SRC recommended that the trial escalate to the next dose level of 22mg capsule No dose-limiting toxicities (DLT’s) or rash observed to date in either capsule or tablet formulations MIAMI, Feb. 05, 2025 — Pasithea […]
MCLEAN, Va., January 30, 2025—-BigBear.ai (NYSE: BBAI), a leader in AI-powered decision intelligence for defense and national security, has been awarded a prime Indefinite Delivery/Indefinite Quantity (IDIQ) contract under the U.S. Department of Navy’s SeaPort […]
Buford, GA, Jan. 30, 2025– ScanTech AI Systems, Inc. (NASDAQ: STAI, ScanTech, or ScanTech AI), a security solutions provider offering one of the world’s most advanced non-intrusive “fixed-gantry” CT screening technologies, proudly announced today the […]
SYDNEY, Jan. 30, 2025 — Kazia Therapeutics Limited (NASDAQ: KZIA) an oncology-focused drug development company, is pleased to announce the regulatory approval and launch of a clinical trial evaluating the combination of paxalisib and immunotherapy in […]
CORNELIUS, N.C., Jan. 06, 2025 — Alpha Modus Holdings, Inc. (NASDAQ: AMOD) (“Alpha Modus” or the “Company”), announces a major milestone with the issuance of its 9th patent, further solidifying its position at the forefront […]
CAMARILLO, CA, Jan. 27, 2025 — NEWTON GOLF Company (NASDAQ: SPGC) (“NEWTON GOLF” or the “Company”), a technology-forward golf company with a growing portfolio of golf products, including putters, golf shafts, golf grips, and other […]
Development advancing to verification and testing phase; Aims to future-proof design, lower componentry costs and improve manufacturing ELMSFORD, N.Y., January 07, 2025—-NanoVibronix, Inc. (NASDAQ: NAOV) (the “Company”), a medical device company that produces the UroShield®, […]
Copyright 1997-2019 Wall Street Reporter / Octagon Media Corp.
